Last updated on November 2018

Study of AMG 673 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia


Brief description of study

This is a first-in-human, open-label, phase 1, sequential dose escalation study. AMG 673 will be evaluated as a short term intravenous (IV) infusion in adult subjects with relapsed/refractory AML. The study will be conducted at approximately 7 sites in the United States, Australia and Germany.

Clinical Study Identifier: NCT03224819

Contact Investigators or Research Sites near you

Start Over

Amgen Call Center

Research Site
Parkville, Australia
7.01miles
  Connect »

Amgen Call Center

Research Site
Melbourne, Australia
7.28miles
  Connect »